BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Up 7.7% Today

What is BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical Inc. ($BMRN) is a biotechnology company focused on developing innovative therapies for rare genetic diseases. Today, the stock experienced a strong bullish movement in the market.

Why is BioMarin Pharmaceutical Inc. going up?

BMRN stock is up 7.7% on Dec 19, 2025 14:35

• The appointment of Rashmi Ramchandani as the new chief accounting officer brings fresh leadership to BioMarin, potentially signaling positive changes within the company.
• Despite concerns about cost-cutting measures and pipeline shifts, investors seem optimistic about BioMarin's future growth prospects, particularly with the Inozyme acquisition and the focus on rare disease treatments.
• The selling of shares by Hudson Bay Capital Management LP and Bellevue Group AG may have initially raised some eyebrows, but the increased holdings by other institutional investors like Dodge & Cox and Viking Global suggest confidence in BioMarin's long-term potential.
• Overall, the market's bullish response to BioMarin today could be attributed to a combination of new leadership, strategic acquisitions, and investor confidence in the company's ability to navigate through its current transformation phase successfully.

BMRN Price Chart

BMRN Technical Analysis

BMRN News

BioMarin appoints Rashmi Ramchandani as chief accounting officer

BioMarin Pharmaceutical Inc. has appointed Rashmi Ramchandani as its new vice president and chief accounting officer, effective January 19, 2026. Ramchandani, previously from Gilead Sciences, will assume the role of principal accounting officer, succeeding Brian Mueller. Her compensation package includes an annual base salary, a sign-on bonus, and eligibility for stock units and options.

https://m.investing.com/news/sec-filings/biomarin-appoints-rashmi-ramchandani-as-chief-accounting-officer-93CH-4413666?ampMode=1

Should BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?

BioMarin Pharmaceutical is undergoing a significant transformation, including a $500 million cost-cutting program and the discontinuation of the Roctavian program, alongside workforce reductions. While analysts acknowledge the Inozyme acquisition could help long-term growth, concerns linger regarding rising competition in achondroplasia and potential pipeline gaps. The company's immediate focus remains on the growth of its rare disease franchise, primarily VOXZOGO, and achieving a 40% non-GAAP operating margin next year.

https://www.sahmcapital.com/news/content/should-biomarins-cost-cuts-roctavian-exit-and-pipeline-shifts-require-action-from-bmrn-investors-2025-12-14

Hudson Bay Capital Management LP Sells 60,425 Shares of BioMarin Pharmaceutical Inc. $BMRN

Hudson Bay Capital Management LP has reduced its stake in BioMarin Pharmaceutical Inc. by selling 60,425 shares, leaving them with 526,420 shares valued at approximately $28.94 million. BioMarin missed quarterly EPS and revenue estimates but provided optimistic FY2025 guidance. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $88.61.

https://www.marketbeat.com/instant-alerts/filing-hudson-bay-capital-management-lp-sells-60425-shares-of-biomarin-pharmaceutical-inc-bmrn-2025-12-13/

BioMarin Pharmaceutical Inc. $BMRN Holdings Lowered by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP reduced its stake in BioMarin Pharmaceutical Inc. ($BMRN) by 10.3% in Q2, while several other major institutional investors, including Dodge & Cox and Viking Global, significantly increased their holdings. Analysts maintain a "Moderate Buy" consensus despite the company missing recent quarterly EPS expectations. Institutional investors now own approximately 98.71% of BioMarin's stock.

https://www.marketbeat.com/instant-alerts/filing-biomarin-pharmaceutical-inc-bmrn-holdings-lowered-by-hudson-bay-capital-management-lp-2025-12-14/

Bellevue Group AG Lowers Stake in BioMarin Pharmaceutical Inc. $BMRN

Bellevue Group AG significantly reduced its stake in BioMarin Pharmaceutical Inc. by 58.9% in Q2, selling 216,928 shares, although other institutional investors like Dodge & Cox, Viking Global, AQR, Geode, and Norges Bank increased their positions. Despite BioMarin missing Q2 EPS and revenue estimates, institutional ownership remains high at 98.71%, and analysts maintain a "Moderate Buy" consensus with an $88.61 target, anticipating a strong FY2025 EPS guidance.

https://www.marketbeat.com/instant-alerts/filing-bellevue-group-ag-lowers-stake-in-biomarin-pharmaceutical-inc-bmrn-2025-12-13/

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.6% Today

QTUM ($QTUM) Crypto Forecast: Up 6.2% Today

Unity Software ($U) Stock Forecast: Up 5.1% Today

Western Digital Corporation ($WDC) Stock Forecast: Up 5.3% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 7.8% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 8.4% Today

Norwegian Cruise Line Holdings Ltd. ($NCLH) Stock Forecast: Up 7.2% Today

Nike Inc. ($NKE) Stock Forecast: Down 11.7% Today

Monero ($XMR) Crypto Forecast: Up 5.3% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 5.1% Today

BioMarin Pharmaceutical Inc. Price History

19.11.2025 - BMRN Stock was up 7.7%

• The appointment of Rashmi Ramchandani as the new chief accounting officer brings fresh leadership to BioMarin, potentially signaling positive changes within the company.
• Despite concerns about cost-cutting measures and pipeline shifts, investors seem optimistic about BioMarin's future growth prospects, particularly with the Inozyme acquisition and the focus on rare disease treatments.
• The selling of shares by Hudson Bay Capital Management LP and Bellevue Group AG may have initially raised some eyebrows, but the increased holdings by other institutional investors like Dodge & Cox and Viking Global suggest confidence in BioMarin's long-term potential.
• Overall, the market's bullish response to BioMarin today could be attributed to a combination of new leadership, strategic acquisitions, and investor confidence in the company's ability to navigate through its current transformation phase successfully.

15.11.2025 - BMRN Stock was down 2.1%

• Hudson Bay Capital Management LP, Bellevue Group AG, and other institutional investors have decreased their stakes in BioMarin Pharmaceutical Inc., possibly indicating concerns about the company's immediate performance outlook.
• Despite falling short of quarterly earnings per share (EPS) estimates, BioMarin's positive guidance for FY2025 and ongoing restructuring efforts have generated optimism among investors. This is evidenced by increased holdings from Dodge & Cox, Viking Global, AQR, Geode, Norges Bank, and Boone Capital Management LLC.
• The market's response to the mixed signals of underperforming earnings but promising future projections implies that investors are considering the company's current obstacles against its growth potential and margin expansion through restructuring and late-stage trials.
• The fluctuation in BioMarin's stock price today results from a combination of short-term profit-taking by some investors and long-term confidence stemming from the company's strategic initiatives and advancements in its pipeline.

16.08.2024 - BMRN Stock was down 8.2%

• The bearish movement in BMRN today may be linked to Ascendis Pharma's positive trial results for a dwarfism treatment, potentially impacting BioMarin's Voxzogo.
• Investors are likely concerned about BioMarin's market share in light of this news.
• Competition in the rare disease drug market is intense, with positive developments from rivals often affecting stock prices.

08.03.2025 - BMRN Stock was down 6.0%

• Today's downward trend in BMRN could be a result of investors taking profits following a period of positive developments and possible overvaluation.
• While the Phase 3 trial results for Palynziq in adolescent patients were encouraging, some investors may have anticipated even better outcomes, leading to selling pressure.
• Comparisons to CSL Limited in terms of valuation might have influenced investor attitudes, prompting some to reconsider their investment allocations in pursuit of perceived better opportunities.
• In conclusion, today's market behavior for BMRN appears to reflect a mix of profit-taking, unmet high expectations, and potential shifts in investor preferences within the sector.

15.00.2025 - BMRN Stock was down 5.3%

• Despite positive projections from financial analysts, BioMarin (BMRN) faced a notable decline in its stock value recently.
• The difference between the optimistic forecasts and the current market performance may be linked to general market sentiment, investor profit-taking, or unexpected negative developments impacting the company.
• Investor response to external factors like regulatory challenges, unsatisfactory clinical trials, or overall market instability likely contributed to the recent drop in BioMarin's stock value.

08.00.2025 - BMRN Stock was up 1.4%

• Investors have been analyzing BMRN alongside TECH to evaluate their investment potential.
• This comparison likely piqued investor interest in BMRN, resulting in heightened buying activity and the observed bullish trend.
• Trader sentiment regarding the relative value of BMRN compared to TECH may have prompted increased bullish positions on BMRN in today's trading session.

04.05.2024 - BMRN Stock was down 0.1%

• The bearish movement in BMRN stock today could be attributed to an executive selling over $3 million in company stock, possibly raising investor concerns about the insider's confidence in the company's future prospects.
• Market reaction to a recent report on the Hereditary Angioedema market may have also had a negative impact on BioMarin Pharmaceutical's market position, leading to uncertainties about its competitive edge in the industry.
• The combination of insider selling and market dynamics related to the Hereditary Angioedema market report likely contributed to the bearish sentiment and downward pressure on BMRN stock today.

06.07.2024 - BMRN Stock was up 8.0%

• BioMarin stock surged following better-than-expected Q2 results, with earnings per share of 96 cents exceeding analyst forecasts.
• Despite a target reduction by TD Cowen, the stock maintained a Buy rating, indicating optimism regarding the company's performance.
• The affirmation of progress and increased full-year guidance during the earnings call bolstered investor confidence in BioMarin's future outlook.
• A robust earnings report, demonstrating revenue of $712.03 million, outpacing analyst predictions, contributed to the positive momentum in BMRN stock.

04.03.2025 - BMRN Stock was down 10.4%

• Despite positive Phase 3 results for Palynziq in lowering blood Phe levels in adolescents, BioMarin's stock saw a bearish trend.
• The market may have reacted negatively due to profit-taking by investors after a recent run-up in the stock price following the positive results.
• Investors might be concerned about the timeline and potential challenges in getting label expansion approval from health authorities despite the promising data.
• The bearish movement could also be influenced by broader market conditions or sector-specific factors impacting biotechnology stocks.

06.07.2024 - BMRN Stock was up 5.4%

• Better-than-expected second-quarter financial results were reported by BioMarin Pharmaceutical, with earnings per share of 96 cents, surpassing the analyst consensus estimate of 35 cents per share.
• The company confirmed progress and raised its full-year guidance, indicating positive momentum and growth prospects.
• The market reacted positively to the earnings beat and optimistic outlook, driving the bullish movement in BMRN stock as investors gained confidence in the company's performance and future potential.

20.01.2025 - BMRN Stock was up 6.3%

• BioMarin's Q4 adjusted EPS exceeding consensus expectations and providing strong sales guidance for 2025 has fueled investor confidence in the company's growth prospects.
• The positive earnings report and future outlook have likely attracted new investors and increased buying interest in the stock.
• The market's reaction indicates that investors are optimistic about BioMarin's ability to deliver on its financial targets and continue its success in developing treatments for rare diseases.

29.09.2025 - BMRN Stock was down 3.3%

• Analysts revised their forecasts for BioMarin Pharmaceutical following lower-than-expected earnings reported for the third quarter.
• Earnings for the quarter were 12 cents per share, missing the analyst consensus estimate of 37 cents per share.
• The unsatisfactory earnings likely shook investor confidence, leading to a bearish movement in the stock price.
• Investors may be worried about the company's future performance and its impact on its pipeline of therapies for rare genetic diseases.